The key finding
Researchers have identified sirtuins—a family of enzymes that act as cellular stress sensors—as potentially significant players in inflammatory bowel disease (IBD) pathogenesis. These enzymes require NAD+, a molecule central to energy metabolism, to function, and studies show that NAD+ metabolism is disrupted in IBD patients. With more than 200 genetic locations already linked to IBD and healthcare costs exceeding $25 billion in the United States alone, understanding how sirtuins influence gut inflammation could open new avenues for managing ulcerative colitis and Crohn’s disease, the two main forms of this chronic condition.
What the study looked like
This 2025 review synthesizes existing research on sirtuins and inflammatory bowel diseases rather than presenting new experimental data. The authors examined studies exploring metabolic changes in IBD patients, particularly focusing on nicotinamide adenine dinucleotide (NAD+) metabolism and sirtuin function. IBD encompasses primarily ulcerative colitis and Crohn’s disease, both characterized by chronic, relapsing inflammation of the gastrointestinal tract. The review draws on genetic studies identifying over 200 loci associated with IBD, as well as metabolic research showing alterations in how patients’ cells produce and use energy. The analysis considers how sirtuins—which modify proteins through processes called deacylation and ADP-ribosylation—interact with various cellular proteins beyond just histones, making them central regulators of cellular stress responses throughout the body.
Why researchers think this happened
The connection between sirtuins and IBD stems from the complex nature of these diseases, which develop through interactions among genetic predisposition, gut microbiota, immune system function, and environmental factors. Because sirtuins require NAD+ as a cofactor to perform their enzymatic work, and NAD+ plays a pivotal role in energy metabolism and cell signaling, disruptions in NAD+ levels directly impact sirtuin function. Researchers propose that sirtuins act as metabolic sensors, responding to cellular stress by modifying key proteins that regulate inflammation and immune responses. When NAD+ metabolism becomes dysregulated in IBD patients, sirtuins may lose their ability to properly control inflammatory processes in the gut. This metabolic dimension adds to the already-known genetic complexity of IBD, suggesting that the disease involves not just immune dysfunction but also fundamental disturbances in how intestinal cells manage energy and respond to stress.
How to read this carefully
This review synthesizes existing research rather than presenting new clinical trial data, so its conclusions represent a framework for understanding potential mechanisms rather than proven treatments. The connection between sirtuins and IBD is based on correlational findings—dysregulated NAD+ metabolism is observed in IBD patients, but this doesn’t establish that sirtuin dysfunction causes the disease or that fixing it would cure patients. The paper describes sirtuins as having a “potential therapeutic role,” which is speculative language indicating early-stage hypothesis rather than clinical evidence. Additionally, the extreme complexity of IBD, with over 200 genetic factors involved, means that any single pathway like sirtuin function likely represents just one piece of a much larger puzzle. Readers should understand this as exploratory science identifying promising research directions, not as evidence for specific interventions.
What this means for everyday life
For the millions living with ulcerative colitis or Crohn’s disease, this research highlights how fundamental cellular energy metabolism might influence gut inflammation. While existing IBD treatments are supportive rather than curative, understanding the sirtuin-NAD+ connection could eventually inform new therapeutic approaches. The finding underscores something increasingly clear in chronic disease research: metabolism and inflammation are deeply intertwined. For now, this knowledge doesn’t translate to specific actions individuals can take, as sirtuin-targeting therapies for IBD remain experimental. However, it reinforces that IBD involves complex biological networks beyond just immune malfunction, potentially explaining why single-target treatments often fall short. As research progresses, this metabolic angle might help explain why some patients respond differently to existing treatments or could point toward combination approaches that address both immune and metabolic dimensions of these challenging conditions.